Anton Neschadim, CEO, ImmunoBiochem Corporation

Recent Developments and Novel Approaches in Oncology and Immuno-Oncology with Anton Neschadim, CEO, ImmunoBiochem Corporation

Tuesday, September 21, 2021 - 6:30pm

Link:
Register in advance for this meeting:
https://utoronto.zoom.us/meeting/register/tZYtdemhrjotGNRJuanGlxPMrk2GdYDxFLIg 

After registering, you will receive a confirmation email containing information about joining the meeting.

Talk Title: 

Recent Developments and Novel Approaches in Oncology and Immuno-Oncology

Biography:

Anton is a biomedical industry leader, scientist, innovator, entrepreneur and venture capital investment professional with more than 15 years of combined industry and academic experience in research, drug development and venture capital. Anton's experience and education bridges business administration and biomedical research, and enabled him to effectively lead and manage therapeutic drug development and R&D efforts in the biotechnology industry. Anton's venture capital investment experience spans deal sourcing, evaluation and due diligence of seed to series A investment opportunities across biotech, health tech and deep tech sectors. With an infinite passion for the transformative benefits of biomedical research and biotechnology to our society, Anton is an integrative thinker employing his multi-disciplinary experience to advance the development of therapeutics that can address significant unmet clinical need. Anton is known for developing novel biological therapeutics and gene therapy treatment modalities, and published scientific works and patents across all major areas of biomedical research, including immunology, oncology, regenerative medicine, gene therapy and biological chemistry.

Abstract:

Concurrent advances in tumor immunology and novel therapeutics modalities have catalyzed the rise of immuno-oncology in the past decade. On the one hand, we have witnessed how new insights from basic immunology have taken flight in the tremendous clinical success of immune checkpoint modulators (or ICMs), with the current focus being on better understanding immunologically “cold” tumor microenvironments, on how to leverage various types of cellular immunity better for anti-cancer therapy, and on innate immunity pathways. On the other hand, we observed how advances in gene and cell therapy as well as gene editing have matured the space of cellular therapeutics. Finally, focus on platform technologies have paved the way for novel, modular modalities that significantly expanded the armamentarium of immune-oncology therapeutics, both biological and cell-based. Harnessing the synergies from bridging these recent advances have enabled a slate of significant clinical successes, which will be highlighted in this module.